NEJM: Trial of a preferential phosphodiesterase 4B inhibitor for idiopathic pulmonary fibrosis

M. Wijsenbeek (Rotterdam, Netherlands)

Source: International Congress 2022 – From the Editor's Desk

Session: From the Editor's Desk
Session type: Journal session
Number: 1362

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Wijsenbeek (Rotterdam, Netherlands). NEJM: Trial of a preferential phosphodiesterase 4B inhibitor for idiopathic pulmonary fibrosis. International Congress 2022 – From the Editor's Desk

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.